MedKoo product information:

 Docetaxel

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

DRUG DESCRIPTION

Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine,N-tert-butyl ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate. Docetaxel is a white to almost-white powder with an empirical formula of C43H53NO14•3H2O, and a molecular weight of 861.9. It is highly lipophilic and practically insoluble in water. TAXOTERE (docetaxel) Injection Concentrate is a clear yellow to brownish-yellow viscous solution. TAXOTERE is sterile, non-pyrogenic, and is available in single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL) docetaxel (anhydrous). Each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80. TAXOTERE Injection Concentrate requires dilution prior to use. A sterile, non-pyrogenic, single-dose diluent is supplied for that purpose. The diluent for TAXOTERE contains 13% ethanol in water for injection, and is supplied in vials.

Mechanism of Action

Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, which results in the inhibition of mitosis in cells. Docetaxel's binding to microtubules does not alter the number of protofilaments in the bound microtubules, a feature which differs from most spindle poisons currently in clinical use.

Formulations and compositions

Docetaxel is a white powder and is the active ingredient available in 20 mg and 80 mg Taxotere single-dose vials of concentrated anhydrous docetaxel in polysorbate 80.  The solution is a clear brown-yellow containing 40 mg docetaxel and 1040 mg polysorbate 80 per mL. 20 mg Taxotere is distributed in a blister carton containing one single-dose vial of Taxotere (docetaxel) preparation in 0.5 mL sterile pyrogen-free anhydrous polysorbate 80, and a single dose Taxotere solvent vial containing 1.5 mL 13% ethanol in saline to be combined and diluted in a 250 mL infusion bag containing 0.9% sodium chloride or 5% glucose for administration. 80 mg Taxotere is supplied identically but with 2.0 mL polysorbate 80 and 6.0 mL 13% ethanol in saline. The docetaxel and solvent vials are combined to give a solution of 10 mg/mL and the required dose is drawn from this solution. Vials have an overfill to compensate for liquid loss during preparation, foaming, adhesion to vial walls and the dead volume. 20 mg vials may be stored for 24 months below 25°C away from light and 80 mg vials for 26 months in the same conditions. Recently Sanofi has got approval for one-vial formulation.  With this one-vial formulation, the preparation of the infusion solution is simplified by eliminating the first dilution step. The two-vial and one-vial formulations contain the same drug substance, docetaxel trihydrate, and the same excipients (ethanol, polysorbate 80 and citric acid). The one-vial formulation is administered as an aqueous intravenous solution that contains the same drug substance in the same concentration as the already approved two-vial formulation. The same grade, quality, and quantity of polysorbate 80 are present in the infusion solution of both formulations. The only difference between these two formulations is the quantity of ethanol. from http://en.wikipedia.org/wiki/Docetaxel.

Discovery, Regulation and Marketing

Taxotere was developed by Rhône-Poulenc Rorer (now Sanofi-Aventis) following from the discoveries of Pierre Potier at CNRS at Gif-sur-Yvette during his work on improvements to the production of Taxol. Docetaxel is currently protected by patents (U.S. patent 4814470, European patent no EP 253738, due to expire in 2010) which are owned by Sanofi-Aventis, and so is available only under the Taxotere brand name internationally. from http://en.wikipedia.org/wiki/Docetaxel.

 Costs

In the UK (in 2009) The cost of 6 cycles (18 weeks) of docetaxel at a dose of 75 mg/m2 IV every 21 days is £5,262 (based on an average body surface area 1.75m2).  from http://en.wikipedia.org/wiki/Docetaxel.  

 1: Ansari J, Hussain SA, Alhasso A, Mahmood R, Ansari A, Glaholm J. Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. Anticancer Agents Med Chem. 2011 Mar;11(3):296-306. Review. PubMed PMID: 21426298.

2: Watanabe M, Nagai Y, Kinoshita K, Saito S, Kurashige J, Karashima R, Hirashima K, Sato N, Imamura Y, Hiyoshi Y, Baba Y, Iwagami S, Miyamoto Y, Iwatsuki M, Hayashi N, Baba H. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion. 2011;83(3):146-52. Epub 2011 Jan 21. Review. PubMed PMID: 21266808.

3: Gan CW, Chien S, Feng SS. Nanomedicine: enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation. Curr Pharm Des. 2010 Jul;16(21):2308-20. Review. PubMed PMID: 20618152.

4: Hensley ML. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Curr Opin Oncol. 2010 Jul;22(4):356-61. Review. PubMed PMID: 20520541.

5: Ulivi P, Arienti C, Zoli W, Scarsella M, Carloni S, Fabbri F, Tesei A, Chiadini E, Orlandi A, Passeri D, Zupi G, Milandri C, Silvestrini R, Amadori D, Leonetti C. In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. Curr Cancer Drug Targets. 2010 Sep;10(6):600-10. Review. PubMed PMID: 20491617.

6: Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol. 2010 Nov;21(11):2135-44. Epub 2010 Mar 29. Review. PubMed PMID: 20351071.

7: Sonpavde G, Sternberg CN. The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. Int J Urol. 2010 Mar;17(3):228-40. Epub 2010 Jan 19. Review. PubMed PMID: 20088874.

8: Armstrong AJ, George DJ. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2010 Jun;13(2):108-16. Epub 2010 Jan 12. Review. PubMed PMID: 20066005.

9: Koolen SL, Beijnen JH, Schellens JH. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Clin Pharmacol Ther. 2010 Jan;87(1):126-9. Epub 2009 Nov 18. Review. PubMed PMID: 19924122.

10: Nishiyama M, Wada S. Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer. 2009;12(3):132-41. Epub 2009 Nov 5. Review. PubMed PMID: 19890692.

11: Chiuri VE, Silvestris N, Lorusso V, Tinelli A. Efficacy and safety of the combination of docetaxel (Taxotere) with targeted therapies in the treatment of solid malignancies. Curr Drug Targets. 2009 Oct;10(10):982-1000. Review. PubMed PMID: 19663766.

12: Caponigro F, Longo F, Perri F, Ionna F. Docetaxel in the management of head and neck cancer. Anticancer Drugs. 2009 Sep;20(8):639-45. Review. PubMed PMID: 19639668.

13: Alsamarai S, Charpidou AG, Matthay RA, Confeld D, Syrigos KN, Saif MW. Pneumonitis related to docetaxel: case report and review of the literature. In Vivo. 2009 Jul-Aug;23(4):635-7. Review. PubMed PMID: 19567400.

14: Lwin Z, Leighl N. Economic evaluation of docetaxel for breast cancer. Expert Opin Pharmacother. 2009 Feb;10(2):283-90. Review. PubMed PMID: 19236199.

15: Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009 Feb;13(1):49-59. Epub 2009 Feb 7. Review. PubMed PMID: 19201649.

16: Wailoo A, Sutton A, Morgan A. The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis. Br J Cancer. 2009 Feb 10;100(3):436-41. Review. PubMed PMID: 19190633; PubMed Central PMCID: PMC2658551.

17: Vici P, Viola G, Botti C, Rossi S, Vitucci C, Corsetti S, Di Lauro L, Sergi D, Foggi P, Perri P, Tirelli C, Mottolese M, Fattoruso SI, Lopez M. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. Clin Ter. 2008 Nov-Dec;159(6):449-52. Review. PubMed PMID: 19169607.

18: Morishita M, Leonard RC. Capecitabine and docetaxel combination for the treatment of breast cancer. Womens Health (Lond Engl). 2008 Jan;4:11-22. Review. PubMed PMID: 19072447.

19: Saloustros E, Mavroudis D, Georgoulias V. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother. 2008 Oct;9(15):2603-16. Review. PubMed PMID: 18803448.

20: Saloustros E, Georgoulias V. Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2008 Aug;8(8):1207-22. Review. PubMed PMID: 18699760.

21: Beardsley EK, Chi KN. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care. 2008 Sep;2(3):161-6. Review. PubMed PMID: 18685415.

22: De Dosso S, Berthold DR. Docetaxel in the management of prostate cancer: current standard of care and future directions. Expert Opin Pharmacother. 2008 Aug;9(11):1969-79. Review. PubMed PMID: 18627334.

23: Strother RM, Sweeney C. Lessons learned from development of docetaxel. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):1007-19. Review. PubMed PMID: 18624687.

24: Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer. 2008 Sep 1;113(5):945-55. Review. PubMed PMID: 18623382.

25: Bernier J, Vrieling C. Docetaxel in the management of patients with head and neck squamous cell carcinoma. Expert Rev Anticancer Ther. 2008 Jul;8(7):1023-32. Review. PubMed PMID: 18588449.

26: Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2008 Jul;12(3):253-68. Epub 2008 May 22. Review. Erratum in: Eur J Oncol Nurs. 2008 Dec;12(5):479. Dosage error in article text. PubMed PMID: 18501674.

27: Montgomery B, Lavori P, Garzotto M, Lee K, Brophy M, Thaneemit-Chen S, Kelly W, Basler J, Ringer R, Yu W, Whittemore A, Lin DW. Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology. 2008 Sep;72(3):474-80. Epub 2008 Apr 14. Review. PubMed PMID: 18407333.

28: Sinibaldi VJ. Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. Clin Interv Aging. 2007;2(4):555-60. Review. PubMed PMID: 18225455; PubMed Central PMCID: PMC2686321.

29: McKeage MJ. The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin Investig Drugs. 2008 Jan;17(1):23-9. Review. PubMed PMID: 18095916.

30: Radaideh SM, Sledge GW. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat. 2008 Sep;111(2):203-8. Epub 2007 Nov 8. Review. PubMed PMID: 17990102.

31: Grande C, Villanueva MJ, Huidobro G, Casal J. Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol. 2007 Sep;9(9):578-81. Review. PubMed PMID: 17921105.

32: Maki RG. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist. 2007 Aug;12(8):999-1006. Review. PubMed PMID: 17766660.

33: Deeks ED, Scott LJ. Docetaxel: in gastric cancer. Drugs. 2007;67(13):1893-901. Review. PubMed PMID: 17722957.

34: Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem. 2007 Jul;2(7):920-42. Review. PubMed PMID: 17530726.

35: Bueno Muiño C, Puente Vázquez J, Sastre Valera J, García-Sáenz JA, Martín M, García Miralles N, Sánchez-Pernaute A, Díaz-Rubio E. Pathological complete response following docetaxel-based neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma. Clin Transl Oncol. 2007 May;9(5):335-8. Review. PubMed PMID: 17525046.

36: Horn L, Visbal A, Leighl NB. Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics. Drugs Aging. 2007;24(5):411-28. Review. PubMed PMID: 17503897.

37: Hernández-Vargas H, Palacios J, Moreno-Bueno G. Telling cells how to die: docetaxel therapy in cancer cell lines. Cell Cycle. 2007 Apr 1;6(7):780-3. Epub 2007 Apr 22. Review. PubMed PMID: 17377494.

38: von Minckwitz G. Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin Pharmacother. 2007 Mar;8(4):485-95. Review. PubMed PMID: 17309343.

39: Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess. 2007 Jan;11(2):iii-iv, xv-xviii, 1-179. Review. PubMed PMID: 17181985.

40: Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs. 2007 Feb;18(2):95-103. Review. PubMed PMID: 17159596.

41: Thuss-Patience PC, Kretzschmar A, Reichardt P. Docetaxel in the treatment of gastric cancer. Future Oncol. 2006 Oct;2(5):603-20. Review. PubMed PMID: 17026452.

42: Mandelblat J, Bashir T, Budman DR. Capecitabine-docetaxel combination treatment. Expert Rev Anticancer Ther. 2006 Sep;6(9):1169-78. Review. PubMed PMID: 17020452.

43: Collins R, Trowman R, Norman G, Light K, Birtle A, Fenwick E, Palmer S, Riemsma R. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. Br J Cancer. 2006 Aug 21;95(4):457-62. Epub 2006 Aug 1. Review. PubMed PMID: 16880788; PubMed Central PMCID: PMC2360673.

44: Ajani JA. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert Opin Pharmacother. 2006 Aug;7(12):1627-31. Review. PubMed PMID: 16872265.

45: Dreicer R. Chemotherapy for advanced prostate cancer: docetaxel and beyond. Hematol Oncol Clin North Am. 2006 Aug;20(4):935-46, x. Review. PubMed PMID: 16861124.

46: Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci. 2006 Sep;97(9):813-20. Epub 2006 Jun 29. Review. PubMed PMID: 16805818.

47: Kintzel PE, Michaud LB, Lange MK. Docetaxel-associated epiphora. Pharmacotherapy. 2006 Jun;26(6):853-67. Review. PubMed PMID: 16716138.

48: Ramaswamy B, Puhalla S. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today (Barc). 2006 Apr;42(4):265-79. Review. PubMed PMID: 16703123.

49: Belani CP. Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel. Lung Cancer. 2005 Dec;50 Suppl 2:S3-8. Review. PubMed PMID: 16557668.

50: Gilbert DC, Parker C. Docetaxel for the treatment of prostate cancer. Future Oncol. 2005 Jun;1(3):307-14. Review. PubMed PMID: 16556003.

51: Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel : recent developments. Clin Pharmacokinet. 2006;45(3):235-52. Review. PubMed PMID: 16509758.

52: Mackler NJ, Pienta KJ. Drug insight: Use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol. 2005 Feb;2(2):92-100; quiz 1 p following 112. Review. PubMed PMID: 16474654.

53: Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS Jr, Lara PN Jr, Mack P, Gumerlock PH, Crowley JJ. Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer. 2005 Dec;7 Suppl 3:S93-7. Review. PubMed PMID: 16384543.

54: Pillot G, Govindan R. The role of docetaxel in N2 locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2005 Dec;7 Suppl 3:S87-92. Review. PubMed PMID: 16384542.

55: Kim ES, Johnson ED. Novel combinations with docetaxel in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2005 Dec;7 Suppl 3:S83-6. Review. PubMed PMID: 16384541.

56: Ramalingam S. First-line chemotherapy for advanced-stage non-small-cell lung cancer: focus on docetaxel. Clin Lung Cancer. 2005 Dec;7 Suppl 3:S77-82. Review. PubMed PMID: 16384540.

57: Petrylak D. Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int. 2005 Dec;96 Suppl 2:41-6. Review. PubMed PMID: 16359438.

58: Doggrell SA. Recent findings with docetaxel in postoperative treatment for breast cancer. Expert Opin Pharmacother. 2005 Dec;6(16):2903-6. Review. PubMed PMID: 16318440.

59: Escobar PF, Rose PG. Docetaxel in ovarian cancer. Expert Opin Pharmacother. 2005 Dec;6(15):2719-26. Review. PubMed PMID: 16316310.

60: Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31. Review. PubMed PMID: 16296875.

61: McKeage K, Keam SJ. Docetaxel in hormone-refractory metastatic prostate cancer. Drugs. 2005;65(16):2287-94; discussion 2295-7. Review. PubMed PMID: 16266195.

62: Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist. 2005 Oct;10(9):665-85. Review. PubMed PMID: 16249346.

63: Borgia F, Guarneri C, Guarneri F, Vaccaro M. Radiation recall dermatitis after docetaxel administration: absolute indication to replace the drug? Br J Dermatol. 2005 Sep;153(3):674-5. Review. PubMed PMID: 16120169.

64: Nabholtz JM, Gligorov J. Docetaxel in the treatment of breast cancer: current experience and future prospects. Expert Rev Anticancer Ther. 2005 Aug;5(4):613-33. Review. PubMed PMID: 16111463.

65: Nabholtz JM, Gligorov J. Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. Expert Opin Pharmacother. 2005 Aug;6(9):1555-64. Review. PubMed PMID: 16086643.

66: Palmeri S, Vaglica M, Spada S, Filippelli G, Farris A, Palmeri L, Massidda B, Misino A, Ferraù F, Comella G, Leonardi V, Condemi G, Mangiameli A, De Cataldis G, Macaluso MC, Cajozzo M, Iannitto E, Danova M. Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study. Oncology. 2005;68(4-6):438-45. Epub 2005 Jul 14. Review. PubMed PMID: 16020974.

67: Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology. 2005;68(4-6):382-90. Epub 2005 Jul 12. Review. PubMed PMID: 16020967.

68: Nisticò C, Cognetti F, Frontini L, Barni S, Ferretti G, Bria E, Milella M, Garufi C, Cuppone F, Vanni B, Carlini P, Terzoli E. Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study. Oncology. 2005;68(4-6):356-63. Epub 2005 Jul 11. Review. PubMed PMID: 16020963.

69: Rigas JR, Dragnev KH, Bubis JA. Docetaxel in the treatment of esophageal cancer. Semin Oncol. 2005 Apr;32(2 Suppl 4):S39-51. Review. PubMed PMID: 16015553.

70: Philip PA. Experience with docetaxel in the treatment of gastric cancer. Semin Oncol. 2005 Apr;32(2 Suppl 4):S24-38. Review. PubMed PMID: 16015552.

71: Lopes G, Rocha Lima CM. Docetaxel in the management of advanced pancreatic cancer. Semin Oncol. 2005 Apr;32(2 Suppl 4):S10-23. Review. PubMed PMID: 16015551.

72: Bekaii-Saab TS, Villalona-Calero MA. Preclinical experience with docetaxel in gastrointestinal cancers. Semin Oncol. 2005 Apr;32(2 Suppl 4):S3-9. Review. PubMed PMID: 16015550.

73: Engels FK, Sparreboom A, Mathot RA, Verweij J. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer. 2005 Jul 25;93(2):173-7. Review. PubMed PMID: 16012521; PubMed Central PMCID: PMC2361544.

74: Chua DT, Sham JS, Au GK. A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2005 Jul;41(6):589-95. Epub 2005 Apr 14. Review. PubMed PMID: 15975521.

75: Engels FK, Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer. 2005 May;41(8):1117-26. Review. PubMed PMID: 15911234.

76: Blagden SP, Kaye SB. Docetaxel in the management of ovarian cancer. Expert Rev Anticancer Ther. 2005 Apr;5(2):203-14. Review. PubMed PMID: 15877518.

77: Wampler MA, Hamolsky D, Hamel K, Melisko M, Topp KS. Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clin J Oncol Nurs. 2005 Apr;9(2):189-93. Review. PubMed PMID: 15853162.

78: Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005 Apr;6(4):229-39. Review. PubMed PMID: 15811618.

79: Heys SD, Sarkar T, Hutcheon AW. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. Breast Cancer Res Treat. 2005 Mar;90(2):169-85. Review. PubMed PMID: 15803364.

80: Van Poppel H. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. Can J Urol. 2005 Feb;12 Suppl 1:81-5. Review. PubMed PMID: 15780173.

81: Wakelee H, Ramalingam S, Belani CP. Docetaxel in advanced non-small cell lung cancer. Expert Rev Anticancer Ther. 2005 Feb;5(1):13-24. Review. PubMed PMID: 15757434.

82: Esmaeli B. Management of excessive tearing as a side effect of docetaxel. Clin Breast Cancer. 2005 Feb;5(6):455-7. Review. PubMed PMID: 15748466.

83: de Wit R. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy. Eur J Cancer. 2005 Mar;41(4):502-7. Epub 2005 Jan 26. Review. PubMed PMID: 15737553.

84: Belani CP, Eckardt J. Development of docetaxel in advanced non-small-cell lung cancer. Lung Cancer. 2004 Dec;46 Suppl 2:S3-11. Review. PubMed PMID: 15698529.

85: Scagliotti GV, Douillard JY. Docetaxel in combined-modality treatment of inoperable locally or regionally advanced lung cancer. Lung Cancer. 2004 Dec;46 Suppl 2:S13-21. Review. PubMed PMID: 15698527.

86: Seidman AD. Gemcitabine and docetaxel in metastatic breast cancer. Oncology (Williston Park). 2004 Dec;18(14 Suppl 12):13-6. Review. PubMed PMID: 15685820.

87: Saeki T, Takashima S. Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer. Breast Cancer. 2004;11(2):116-20. Review. PubMed PMID: 15550855.

88: Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist. 2004;9(5):538-45. Review. PubMed PMID: 15477638.

89: Heys SD, Sarkar T, Hutcheon AW. Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer. Expert Opin Pharmacother. 2004 Oct;5(10):2147-57. Review. PubMed PMID: 15461550.

90: Yardley DA. Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer. Semin Oncol. 2004 Apr;31(2 Suppl 5):37-44. Review. PubMed PMID: 15199531.

91: Alexopoulos A, Karamouzis MV, Rigatos G. In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: general concepts and future perspectives. Semin Oncol. 2004 Apr;31(2 Suppl 5):25-30. Review. PubMed PMID: 15199529.

92: Mathew P, Fidler IJ, Logothetis CJ. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol. 2004 Apr;31(2 Suppl 6):24-9. Review. PubMed PMID: 15176001.

93: Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist. 2004;9 Suppl 2:24-32. Review. PubMed PMID: 15161988.

94: D'Amato G, Rocha Lima C, Mahany JJ, Muro-Cacho C, Haura EB. Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature. Lung Cancer. 2004 Jun;44(3):381-90. Review. PubMed PMID: 15140552.

95: DeGrendele H. Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002. Clin Prostate Cancer. 2003 Mar;1(4):212-4. Review. PubMed PMID: 15040878.

96: Rocha Lima CM, Rizvi NA, Zhang C, Herndon JE 2nd, Crawford J, Govindan R, King GW, Green MR; Cancer Leukemia Group B. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann Oncol. 2004 Mar;15(3):410-8. Review. PubMed PMID: 14998842.

97: Nabell L, Spencer S. Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol. 2003 Dec;30(6 Suppl 18):89-93. Review. PubMed PMID: 14727247.

98: Di Cosimo S, Ferretti G, Fazio N, Silvestris N, Carlini P, Alimonti A, Gelibter A, Felici A, Papaldo P, Cognetti F. Docetaxel in advanced gastric cancer--review of the main clinical trials. Acta Oncol. 2003;42(7):693-700. Review. PubMed PMID: 14690154.

99: Mäenpää JU. Docetaxel: promising and novel combinations in ovarian cancer. Br J Cancer. 2003 Dec;89 Suppl 3:S29-34. Review. PubMed PMID: 14661044; PubMed Central PMCID: PMC2750617.

100: Katsumata N. Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer. 2003 Dec;89 Suppl 3:S9-S15. Review. PubMed PMID: 14661041; PubMed Central PMCID: PMC2750619.

101: Fitzpatrick FA, Wheeler R. The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol. 2003 Dec;3(13-14):1699-714. Review. PubMed PMID: 14636822.

102: Ninomiya J, Horiguchi J, Koibuchi Y, Yoshida T, Iijima K, Yoshida M, Takata D, Yokoe T, Iino Y, Morishita Y. Long-term suppression of lymphangitic lung metastasis from breast cancer using biweekly docetaxel: a case report. Breast Cancer. 2003;10(4):361-5. Review. PubMed PMID: 14634516.

103: Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol. 2003 Nov;170(5):1709-16. Review. PubMed PMID: 14532760.

104: Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev. 2003 Oct;29(5):407-15. Review. PubMed PMID: 12972359.

105: Scagliotti GV, Turrisi AT 3rd. Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer. Oncologist. 2003;8(4):361-74. Review. PubMed PMID: 12897333.

106: Hutcheon AW, Heys SD, Sarkar TK; Aberdeen Breast Group. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat. 2003;79 Suppl 1:S19-24. Review. PubMed PMID: 12868802.

107: Nabholtz JM. Docetaxel-anthracycline combinations in metastatic breast cancer. Breast Cancer Res Treat. 2003;79 Suppl 1:S3-9. Review. PubMed PMID: 12868800.

108: Beer TM, El-Geneidi M, Eilers KM. Docetaxel (taxotere) in the treatment of prostate cancer. Expert Rev Anticancer Ther. 2003 Jun;3(3):261-8. Review. PubMed PMID: 12820771.

109: Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol. 2003;14 Suppl 2:ii41-4. Review. PubMed PMID: 12810457.

110: Chen GY, Chang TW, Chen WC. Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases. Br J Dermatol. 2003 May;148(5):1071-3. Review. PubMed PMID: 12786853.

111: Fumoleau P. Gemcitabine combined with docetaxel in metastatic breast cancer. Semin Oncol. 2003 Apr;30(2 Suppl 3):15-8. Review. PubMed PMID: 12722020.

112: Davies AM, Lara PN Jr, Mack PC, Gandara DR. Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother. 2003 Apr;4(4):553-65. Review. PubMed PMID: 12667118.

113: Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Cancer Biol Ther. 2002 Nov-Dec;1(6):646-51. Review. PubMed PMID: 12642688.

114: Kosmas C, Tsavaris N, Mylonakis N, Kalofonos HP. An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer. Crit Rev Oncol Hematol. 2003 Mar;45(3):265-75. Review. PubMed PMID: 12633839.

115: Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L, Goguen LA, Sullivan CA, Costello R, Case MA, Posner MR. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist. 2003;8(1):35-44. Review. PubMed PMID: 12604730.

116: Posner MR, Lefebvre JL. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. 2003 Jan 13;88(1):11-7. Review. PubMed PMID: 12556952; PubMed Central PMCID: PMC2376785.

117: Kuroi K, Bando H, Saji S, Toi M. Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity. Breast Cancer. 2003;10(1):10-4. Review. PubMed PMID: 12525757.

118: Morris MJ, Santamauro J, Shia J, Schwartz L, Vander Els N, Kelly K, Scher H. Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. Urology. 2002 Dec;60(6):1111. Review. PubMed PMID: 12475686.

119: Di Leo A. The European experience with docetaxel in the treatment of early-stage breast cancer. Clin Breast Cancer. 2002 Oct;3 Suppl 2:S59-62. Review. PubMed PMID: 12435289.

120: O'Shaughnessy J. Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Williston Park). 2002 Oct;16(10 Suppl 12):17-22. Review. PubMed PMID: 12435175.

121: Nicolopoulos J, Howard A. Docetaxel-induced nail dystrophy. Australas J Dermatol. 2002 Nov;43(4):293-6. Review. PubMed PMID: 12423438.

122: Jacobs AD. Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations. Cancer. 2002 Aug 15;95(4 Suppl):923-7. Review. PubMed PMID: 12209672.

123: Koukourakis MI, Romanidis K, Froudarakis M, Kyrgias G, Koukourakis GV, Retalis G, Bahlitzanakis N. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer. 2002 Aug 12;87(4):385-92. Review. PubMed PMID: 12177774; PubMed Central PMCID: PMC2376133.

124: Nabholtz JM, Reese DM, Lindsay MA, Riva A. Docetaxel in the treatment of breast cancer: an update on recent studies. Semin Oncol. 2002 Jun;29(3 Suppl 12):28-34. Review. PubMed PMID: 12170449.

125: Kaye SB, Vasey PA. Docetaxel in ovarian cancer: phase III perspectives and future development. Semin Oncol. 2002 Jun;29(3 Suppl 12):22-7. Review. PubMed PMID: 12170448.

126: Green MR. Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer. Semin Oncol. 2002 Jun;29(3 Suppl 12):17-21. Review. PubMed PMID: 12170447.

127: Belani CP; TAX 326 Study Group. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Semin Oncol. 2002 Jun;29(3 Suppl 12):4-9. Review. PubMed PMID: 12170445.

128: Hortobagyi GN, Kris MG. Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers. Semin Oncol. 2002 Jun;29(3 Suppl 12):1-3. Review. PubMed PMID: 12170444.

129: Font A, Sanchez JM, Rosell R, Taron M, Martinez E, Guillot M, Manzano JL, Margeli M, Barnadas A, Abad A. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Lung Cancer. 2002 Aug;37(2):213-8. Review. PubMed PMID: 12140145.

130: Kim ES, Khuri FR. Docetaxel and radiation as combined-modality therapy. Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):97-105. Review. PubMed PMID: 12108904.

131: Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):89-96. Review. PubMed PMID: 12108902.

132: Glisson BS. The role of docetaxel in the management of squamous cell cancer of the head and neck. Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):83-7. Review. PubMed PMID: 12108901.

133: Kavanagh JJ. Docetaxel in the treatment of ovarian cancer. Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):73-81. Review. PubMed PMID: 12108900.

134: Logothetis CJ. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):63-72. Review. PubMed PMID: 12108899.

135: Khuri FR. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy. Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):53-62. Review. PubMed PMID: 12108898.

136: Fossella FV. Docetaxel for previously treated non-small-cell lung cancer. Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):45-51. Review. PubMed PMID: 12108897.

137: Valero V. Primary chemotherapy with docetaxel for the management of breast cancer. Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):35-43. Review. PubMed PMID: 12108896.

138: Hortobagyi GN. Integration of docetaxel into adjuvant breast cancer treatment regimens. Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):27-33. Review. PubMed PMID: 12108895.

139: Esteva FJ. The current status of docetaxel for metastatic breast cancer. Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):17-26. Review. PubMed PMID: 12108894.

140: Logothetis C, Millikan R. Docetaxel in the management of advanced or metastatic urothelial tract cancer. Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):107-11. Review. PubMed PMID: 12108893.

141: Beer TM, Bubalo JS. Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer. Curr Urol Rep. 2002 Jun;3(3):232-8. Review. PubMed PMID: 12084194.

142: Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Health Technol Assess. 2001;5(32):1-195. Review. PubMed PMID: 12065068.

143: Haller DG, Misset JL. Docetaxel in advanced gastric cancer. Anticancer Drugs. 2002 Jun;13(5):451-60. Review. PubMed PMID: 12045456.

144: Gradishar WJ. Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer. Clin Breast Cancer. 2001 Oct;2 Suppl 1:S31-5. Review. PubMed PMID: 11970742.

145: Bunn PA Jr, Chan DC, Earle K, Zhao TL, Helfrich B, Kelly K, Piazza G, Whitehead CM, Pamukcu R, Thompson W, Alila H. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin Oncol. 2002 Feb;29(1 Suppl 4):87-94. Review. PubMed PMID: 11894018.

146: Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax. 2002 Jan;57(1):20-8. Review. PubMed PMID: 11809985; PubMed Central PMCID: PMC1746188.

147: Senzer NN. Prostate cancer: multimodality approaches with docetaxel. Semin Oncol. 2001 Aug;28(4 Suppl 15):77-85. Review. PubMed PMID: 11685734.

148: Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol. 2001 Aug;28(4 Suppl 15):3-7. Review. PubMed PMID: 11685722.

149: Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am. 2001 Jun;15(3):525-45. Review. PubMed PMID: 11525295.

150: Lynch TJ Jr. Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer. Semin Oncol. 2001 Jun;28(3 Suppl 9):5-9. Review. PubMed PMID: 11444253.

151: Gandara DR, Lara PN Jr, Goldberg Z, Lau DH. Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel. Semin Oncol. 2001 Jun;28(3 Suppl 9):26-32. Review. PubMed PMID: 11441412.

152: Hainsworth JD, Burris HA 3rd, Greco FA. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer. Semin Oncol. 2001 Jun;28(3 Suppl 9):21-5. Review. PubMed PMID: 11441411.

153: Rigas JR. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan. Semin Oncol. 2001 Jun;28(3 Suppl 9):15-20. Review. PubMed PMID: 11441410.

154: Belani C; TAX 326 Study Group. Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis. Semin Oncol. 2001 Jun;28(3 Suppl 9):10-4. Review. PubMed PMID: 11441409.

155: Vigano L, Locatelli A, Grasselli G, Gianni L. Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy. Invest New Drugs. 2001 May;19(2):179-96. Review. PubMed PMID: 11392452.

156: Bruno R, Vivier N, Veyrat-Follet C, Montay G, Rhodes GR. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs. 2001 May;19(2):163-9. Review. PubMed PMID: 11392450.

157: Tolcher AW. Novel compounds in the therapy of breast cancer: opportunities for integration with docetaxel. Oncologist. 2001;6 Suppl 3:40-4. Review. PubMed PMID: 11346685.

158: Baselga J, Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist. 2001;6 Suppl 3:26-9. Review. PubMed PMID: 11346682.

159: Pegram MD. Docetaxel and herceptin: foundation for future strategies. Oncologist. 2001;6 Suppl 3:22-5. Review. PubMed PMID: 11346681.

160: Crown J. Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist. 2001;6 Suppl 3:17-21. Review. PubMed PMID: 11346680.

161: Sessa C, Pagani O. Docetaxel and epirubicin in advanced breast cancer. Oncologist. 2001;6 Suppl 3:13-6. Review. PubMed PMID: 11346679.

162: Crown J. Docetaxel: overview of an active drug for breast cancer. Oncologist. 2001;6 Suppl 3:1-4. Review. PubMed PMID: 11346677.

163: Posner MR. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs. 2001 Feb;12 Suppl 1:S21-4. Review. PubMed PMID: 11340900.

164: Small EJ. Docetaxel in prostate cancer. Anticancer Drugs. 2001 Feb;12 Suppl 1:S17-20. Review. PubMed PMID: 11340899.

165: Green MR. The current status of docetaxel for advanced non-small cell lung cancer. Anticancer Drugs. 2001 Feb;12 Suppl 1:S11-6. Review. PubMed PMID: 11340898.

166: Aapro M, Rowinsky E. Docetaxel: assessing a range of activity. Anticancer Drugs. 2001 Feb;12 Suppl 1:S1-3. Review. PubMed PMID: 11340897.

167: Mileshkin L, Prince HM, Rischin D, Zimet A. Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Bone Marrow Transplant. 2001 Mar;27(5):559-63. Review. PubMed PMID: 11313694.

168: Burris HA 3rd. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol. 2001 Feb;28(1 Suppl 3):38-44. Review. PubMed PMID: 11301373.

169: Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol. 2001 Feb;28(1 Suppl 2):4-9. Review. PubMed PMID: 11284623.

170: Hainsworth JD, Vokes EE. Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. Semin Oncol. 2001 Feb;28(1 Suppl 2):22-7. Review. PubMed PMID: 11284621.

171: Georgoulias V, Scagliotti G, Miller V, Eckardt J, Douillard JY, Manegold C. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. Semin Oncol. 2001 Feb;28(1 Suppl 2):15-21. Review. PubMed PMID: 11284620.

172: Belani C, Lynch T. Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management. Semin Oncol. 2001 Feb;28(1 Suppl 2):10-4. Review. PubMed PMID: 11284619.

173: Georgoulias VA. Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):18-24. Review. PubMed PMID: 11252884.

174: Rocha Lima CM, Urbanic JJ, Sherman CA, Brescia FJ, Green MR. Docetaxel followed by gemcitabine and irinotecan in solid tumors. Oncology (Williston Park). 2001 Jan;15(1 Suppl 1):37-45. Review. PubMed PMID: 11221020.

175: Bernstein BJ. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions. Ann Pharmacother. 2000 Nov;34(11):1332-5. Review. PubMed PMID: 11098349.

176: Comer AM, Goa KL. Docetaxel: a review of its use in non-small cell lung cancer. Drugs Aging. 2000 Jul;17(1):53-80. Review. PubMed PMID: 10933515.

177: Apfel SC. Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors. Cancer Invest. 2000;18(6):564-73. Review. PubMed PMID: 10923105.

178: Armand JP. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme? Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:223-30. Review. PubMed PMID: 10895158.

179: Langer CJ. Advanced non-small cell lung carcinoma: the emerging role of docetaxel. Invest New Drugs. 2000 Feb;18(1):17-28. Review. PubMed PMID: 10830138.

180: Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol. 2000 Apr;27(2 Suppl 3):24-9. Review. PubMed PMID: 10810935.

181: Burris HA 3rd. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin). Semin Oncol. 2000 Apr;27(2 Suppl 3):19-23. Review. PubMed PMID: 10810934.

182: Nabholtz JM, North S, Smylie M, Mackey J, Au HJ, Au R, Morrish D, Salter E, Tonkin K. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. Semin Oncol. 2000 Apr;27(2 Suppl 3):11-8. Review. PubMed PMID: 10810933.

183: Miller VA, Kris MG. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer. Semin Oncol. 2000 Apr;27(2 Suppl 3):3-10. Review. PubMed PMID: 10810932.

184: Burris HA 3rd. Docetaxel (Taxotere) in the treatment of cancer. Semin Oncol. 2000 Apr;27(2 Suppl 3):1-2. Review. PubMed PMID: 10810931.

185: Gridelli C, Frontini L, Barletta E, Rossi A, Barzelloni ML, Scognamiglio F, Guida C, Gatani T, Fiore F, De Bellis M, Marfella A, Manzione L. Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature. Anticancer Res. 2000 Mar-Apr;20(2B):1077-84. Review. PubMed PMID: 10810400.

186: Belani CP. Paclitaxel and docetaxel combinations in non-small cell lung cancer. Chest. 2000 Apr;117(4 Suppl 1):144S-151S. Review. PubMed PMID: 10777470.

187: Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer. Drugs. 2000 Mar;59(3):621-51. Review. PubMed PMID: 10776837.

188: Oh WK, Kantoff PW. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. Semin Oncol. 1999 Oct;26(5 Suppl 17):49-54. Review. PubMed PMID: 10604270.

189: Kreis W, Budman D. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer. Semin Oncol. 1999 Oct;26(5 Suppl 17):34-8. Review. PubMed PMID: 10604267.

190: Earhart RH. Docetaxel (Taxotere): preclinical and general clinical information. Semin Oncol. 1999 Oct;26(5 Suppl 17):8-13. Review. PubMed PMID: 10604262.

191: Adjei AA, Argiris A, Murren JR. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer. Semin Oncol. 1999 Oct;26(5 Suppl 16):32-40; discussion 41-2. Review. PubMed PMID: 10585007.

192: Rizvi NA, Spiridonidis CH, Davis TH, Bhargava P, Marshall JL, Dahut W, Figuera M, Hawkins MJ. Docetaxel and gemcitabine combinations in non-small cell lung cancer. Semin Oncol. 1999 Oct;26(5 Suppl 16):27-31; discussion 41-2. Review. PubMed PMID: 10585006.

193: Krug LM, Miller VA. Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer. Semin Oncol. 1999 Oct;26(5 Suppl 16):24-6; discussion 41-2. Review. PubMed PMID: 10585005.

194: Fossella FV. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials. Semin Oncol. 1999 Oct;26(5 Suppl 16):17-23; discussion 41-2. Review. PubMed PMID: 10585004.

195: Ornstein DL, Nervi AM, Rigas JR. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program. Ann Oncol. 1999;10 Suppl 5:S35-40. Review. PubMed PMID: 10582137.

196: Couteau C, Chouaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C, Groult V, Bordessoule S, Janot F, De Forni M, Armand JP. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 1999 Oct;81(3):457-62. Review. PubMed PMID: 10507770; PubMed Central PMCID: PMC2362927.

197: Rosell R. New approaches in the adjuvant and neoadjuvant therapy of non-small cell lung cancer, including docetaxel (Taxotere) combinations. Semin Oncol. 1999 Jun;26(3 Suppl 11):32-7. Review. PubMed PMID: 10458209.

198: Manegold C. Docetaxel (Taxotere) in non-small cell lung cancer: ongoing studies in Heidelberg and future plans. Semin Oncol. 1999 Jun;26(3 Suppl 11):23-7. Review. PubMed PMID: 10458207.

199: Rizvi NA. Docetaxel (Taxotere) and gemcitabine in combination therapy. Semin Oncol. 1999 Jun;26(3 Suppl 11):19-22. Review. PubMed PMID: 10458206.

200: Fossella FV. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer. Semin Oncol. 1999 Jun;26(3 Suppl 11):4-8. Review. PubMed PMID: 10458203.

201: Hainsworth JD, Burris HA 3rd, Greco FA. Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Oncol. 1999 Jun;26(3 Suppl 10):19-24. Review. PubMed PMID: 10437747.

202: Mattson K. Docetaxel (Taxotere) and neoadjuvant chemotherapy for non-small cell lung cancer. Semin Oncol. 1999 Jun;26(3 Suppl 10):25-8. Review. PubMed PMID: 10437748.

203: Belani CP. Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments. Semin Oncol. 1999 Jun;26(3 Suppl 10):15-8. Review. PubMed PMID: 10437746.

204: van Oosterom AT. Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies. Semin Oncol. 1999 Jun;26(3 Suppl 10):8-11. Review. PubMed PMID: 10437744.

205: Gandara DR, Edelman MJ, Lau D. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer. Semin Oncol. 1999 Jun;26(3 Suppl 10):3-7. Review. PubMed PMID: 10437743.

206: Burris HA 3rd. Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol. 1999 Jun;26(3 Suppl 9):1-6. Review. PubMed PMID: 10426452.

207: Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol. 1999 Jun;26(3 Suppl 9):32-6. Review. PubMed PMID: 10426457.

208: Costa SD, von Minckwitz G, Raab G, Blohmer JU, Dresel V, Eidtmann H, Hilfrich J, Jackisch C, Merkle E, Gademann G, Kaufmann M. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol. 1999 Jun;26(3 Suppl 9):24-31. Review. PubMed PMID: 10426456.

209: Ravdin PM. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer. Semin Oncol. 1999 Jun;26(3 Suppl 9):20-3. Review. PubMed PMID: 10426455.

210: Nabholtz JM. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Semin Oncol. 1999 Jun;26(3 Suppl 9):7-13. Review. PubMed PMID: 10426453.

211: Nabholtz JM, Smylie M, Mackey J, Au HJ, Tonkin K, Au R, Morrish D, Salter E. Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer. Semin Oncol. 1999 Jun;26(3 Suppl 8):47-52. Review. PubMed PMID: 10403474.

212: Crown J. Phase III randomized trials of docetaxel in patients with metastatic breast cancer. Semin Oncol. 1999 Jun;26(3 Suppl 8):33-8. Review. PubMed PMID: 10403472.

213: Trudeau ME. Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer. Semin Oncol. 1999 Jun;26(3 Suppl 8):21-6. Review. PubMed PMID: 10403470.

214: Pivot X, Asmar L, Hortobagyi GN. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review). Int J Oncol. 1999 Aug;15(2):381-6. Review. PubMed PMID: 10402251.

215: Lamb HM, Wiseman LR. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer. Pharmacoeconomics. 1998 Oct;14(4):447-59. Review. PubMed PMID: 10344911.

216: Nabholtz JM, Tonkin K, Smylie M, Mackey J, Janowska-Wieczorek A. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting. Semin Oncol. 1999 Feb;26(1 Suppl 3):10-6. Review. PubMed PMID: 10203265.

217: Crown J. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer. Semin Oncol. 1999 Feb;26(1 Suppl 3):5-9. Review. PubMed PMID: 10203264.

218: Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999 Feb;36(2):99-114. Review. PubMed PMID: 10092957.

219: Schöffski P, Weihkopf T, Ganser A. Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel. Anticancer Res. 1998 Nov-Dec;18(6B):4751-6. Review. PubMed PMID: 9891552.

220: Hortobagyi G. An expanding role for docetaxel. Semin Oncol. 1998 Dec;25(6 Suppl 13):1-3. Review. PubMed PMID: 9865684.

221: Crommentuyn KM, Schellens JH, van den Berg JD, Beijnen JH. In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. Cancer Treat Rev. 1998 Oct;24(5):345-66. Review. PubMed PMID: 9861197.

222: Colevas AD, Posner MR. Docetaxel in head and neck cancer: a review. Am J Clin Oncol. 1998 Oct;21(5):482-6. Review. PubMed PMID: 9781605.

223: Tankanow RM. Docetaxel: a taxoid for the treatment of metastatic breast cancer. Am J Health Syst Pharm. 1998 Sep 1;55(17):1777-91. Review. PubMed PMID: 9775340.

224: Miller VA. Docetaxel in the management of advanced non-small cell lung cancer. Semin Oncol. 1998 Jun;25(3 Suppl 8):15-9. Review. PubMed PMID: 9704671.

225: Drings P, Büchholz E, Manegold C. Ifosfamide and docetaxel in non-small cell lung cancer. Semin Oncol. 1998 Feb;25(1 Suppl 2):29-37. Review. PubMed PMID: 9535209.

226: Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs. 1998 Jan;9(1):1-17. Review. PubMed PMID: 9491787.

227: Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. Eur J Cancer. 1997 Nov;33(13):2167-70. Review. PubMed PMID: 9470802.

228: Fumoleau P. Efficacy and safety of docetaxel in clinical trials. Am J Health Syst Pharm. 1997 Dec 15;54(24 Suppl 2):S19-24. Review. PubMed PMID: 9435929.

229: Bruno R, Riva A, Hille D, Lebecq A, Thomas L. Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials. Am J Health Syst Pharm. 1997 Dec 15;54(24 Suppl 2):S16-9. Review. PubMed PMID: 9435928.

230: Kraynak MA. Pharmaceutical aspects of docetaxel. Am J Health Syst Pharm. 1997 Dec 15;54(24 Suppl 2):S7-10. Review. PubMed PMID: 9435926.

231: Eckardt JR. Antitumor activity of docetaxel. Am J Health Syst Pharm. 1997 Dec 15;54(24 Suppl 2):S2-6. Review. PubMed PMID: 9435925.

232: Marty M, Extra JM, Cottu PH, Espié M. Prospects with docetaxel in the treatment of patients with breast cancer. Eur J Cancer. 1997 Aug;33 Suppl 7:S26-9. Review. PubMed PMID: 9486101.

233: Diéras V, Fumoleau P, Kalla S, Misset JL, Azli N, Pouillart P. Docetaxel in combination with doxorubicin or vinorelbine. Eur J Cancer. 1997 Aug;33 Suppl 7:S20-2. Review. PubMed PMID: 9486099.

234: Ravdin PM. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients. Eur J Cancer. 1997 Aug;33 Suppl 7:S7-10. Review. PubMed PMID: 9486096.

235: Rubens RD. The role of docetaxel in improving treatment outcomes in advanced breast cancer. Eur J Cancer. 1997 Aug;33 Suppl 7:S1-2. Review. PubMed PMID: 9486094.

236: Burris HA 3rd. Docetaxel in combination with fluorouracil for advanced solid tumors. Oncology (Williston Park). 1997 Aug;11(8 Suppl 8):50-2. Review. PubMed PMID: 9364544.

237: Aapro MS. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer. Oncology (Williston Park). 1997 Aug;11(8 Suppl 8):46-9. Review. PubMed PMID: 9364543.

238: Belani CP. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer. Oncology (Williston Park). 1997 Aug;11(8 Suppl 8):42-5. Review. PubMed PMID: 9364542.

239: Diéras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997 Aug;11(8 Suppl 8):31-3. Review. PubMed PMID: 9364539.

240: D'Andrea GM, Seidman AD. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. Semin Oncol. 1997 Aug;24(4 Suppl 13):S13-27-S13-44. Review. PubMed PMID: 9335514.

241: Khayat D, Antoine E. Docetaxel in combination chemotherapy for metastatic breast cancer. Semin Oncol. 1997 Aug;24(4 Suppl 13):S13-19-S13-26. Review. PubMed PMID: 9335513.

242: Valero V. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol. 1997 Aug;24(4 Suppl 13):S13-11-S13-18. Review. PubMed PMID: 9335512.

243: Piccart MJ, Di Leo A. Future perspectives of docetaxel (Taxotere) in front-line therapy. Semin Oncol. 1997 Aug;24(4 Suppl 10):S10-27-S10-33. Review. PubMed PMID: 9275004.

244: Ravdin PM. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer. Semin Oncol. 1997 Aug;24(4 Suppl 10):S10-18-S10-21. Review. PubMed PMID: 9275002.

245: Antoine EC, Rixe O, Auclerc G, Weil M, Khayat D. Docetaxel. A review of its role in breast cancer treatment. Am J Clin Oncol. 1997 Aug;20(4):429-32. Review. PubMed PMID: 9256905.

246: Paclitaxel and docetaxel in breast and ovarian cancer. Drug Ther Bull. 1997 Jun;35(6):43-6. Review. PubMed PMID: 9282422.

247: Hortobágyi G. Docetaxel in breast cancer and a rationale for combination therapy. Oncology (Williston Park). 1997 Jun;11(6 Suppl 6):11-5. Review. PubMed PMID: 9213321.

248: MacConnachie AM. Docetaxel (taxotere, Rhone-Poulenc Rorer). Intensive Crit Care Nurs. 1997 Apr;13(2):119-20. Review. PubMed PMID: 9180501.

249: Hui YF, Ignoffo RJ. Docetaxel in anthracycline-resistant metastatic breast cancer. Cancer Pract. 1997 Mar-Apr;5(2):124-7. Review. PubMed PMID: 9110651.

250: Ravdin PM. The international experience with docetaxel in the treatment of breast cancer. Oncology (Williston Park). 1997 Mar;11(3 Suppl 2):38-42. Review. PubMed PMID: 9110341.

251: Balat O, Kudelka AP, Edwards CL, Verschraegen CF, Kavanagh JJ. Prolonged remission of platinum-refractory ovarian cancer with docetaxel: brief report and review of literature. Eur J Gynaecol Oncol. 1997;18(5):341-2. Review. PubMed PMID: 9378149.

252: Docetaxel (Taxotere) for advanced breast cancer. Med Lett Drugs Ther. 1996 Sep 27;38(984):87-8. Review. PubMed PMID: 8828520.

253: Armand JP. The clinical rationale for developing docetaxel (Taxotere). Anticancer Drugs. 1996 Aug;7 Suppl 2:37-9. Review. PubMed PMID: 8862710.

254: Burris HA. Optimal use of docetaxel (Taxotere): maximizing its potential. Anticancer Drugs. 1996 Aug;7 Suppl 2:25-8. Review. PubMed PMID: 8862707.

255: Trudeau ME. Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol. 1996 Jun;6(1):443-57. Review. PubMed PMID: 8853517.

256: Fulton B, Spencer CM. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs. 1996 Jun;51(6):1075-92. Review. PubMed PMID: 8736622.

257: Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995 Oct;13(10):2643-55. Review. PubMed PMID: 7595719.

258: Pronk LC, Stoter G, Verweij J. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. Cancer Treat Rev. 1995 Sep;21(5):463-78. Review. PubMed PMID: 8556719.

259: Rougier P. Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Anticancer Drugs. 1995 Jul;6 Suppl 4:25-9. Review. PubMed PMID: 8745351.

260: Le Chevalier T. Docetaxel: meeting the challenge of non-small cell lung cancer management. Anticancer Drugs. 1995 Jul;6 Suppl 4:13-7. Review. PubMed PMID: 8745349.

261: Piccart M. Docetaxel: a new defence in the management of breast cancer. Anticancer Drugs. 1995 Jul;6 Suppl 4:7-11. Review. PubMed PMID: 8745348.

262: van Oosterom AT, Schrijvers D, Schriivers D [corrected to Schrijvers D. Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. Anticancer Drugs. 1995 Jun;6(3):356-68. Review. Erratum in: Anticancer Drugs 1995 Aug;6(4):618. PubMed PMID: 7670133.

263: Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs. 1995 Jun;6(3):339-55, 363-8. Review. PubMed PMID: 7670132.

264: Kaye SB. Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer. Semin Oncol. 1995 Apr;22(2 Suppl 4):30-3. Review. PubMed PMID: 7740329.

265: Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, André S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995 Apr;22(2 Suppl 4):3-16. Review. PubMed PMID: 7740328.

266: Fossella FV, Lee JS, Berille J, Hong WK. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol. 1995 Apr;22(2 Suppl 4):22-9. Review. PubMed PMID: 7740327.

267: Ravdin PM, Valero V. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. Semin Oncol. 1995 Apr;22(2 Suppl 4):17-21. Review. PubMed PMID: 7740326.

268: Francis PA, Kris MG, Rigas JR, Grant SC, Miller VA. Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Lung Cancer. 1995 Apr;12 Suppl 1:S163-72. Review. PubMed PMID: 7551925.

269: Fumoleau P, Chevallier B, Kerbrat P, Dieras V, Azli N, Bayssas M, Van Glabbeke M. Current status of Taxotere (docetaxel) as a new treatment in breast cancer. Breast Cancer Res Treat. 1995;33(1):39-46. Review. PubMed PMID: 7749131.

270: Aapro M, Bruno R. Early clinical studies with docetaxel. Docetaxel Investigators Group. Eur J Cancer. 1995;31A Suppl 4:S7-10. Review. PubMed PMID: 7577102.

271: Bissery MC. Preclinical pharmacology of docetaxel. Eur J Cancer. 1995;31A Suppl 4:S1-6. Review. PubMed PMID: 7577097.

272: Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 1994 Nov 5;344(8932):1267-72. Review. PubMed PMID: 7967989.

273: Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol. 1994 Jul;5(6):495-505. Review. PubMed PMID: 7918121.

274: Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev. 1993 Oct;19(4):351-86. Review. PubMed PMID: 8106152.

275: Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv. 1993;17:305-13. Review. PubMed PMID: 7907950.